BRPI0413676B8 - compostos derivados de oxazol e oxadiazol e composições farmacêuticas úteis para a liberação oral de composto de peptídeo semelhante a glucagon-1 (glp-1) ou de peptídeo agonista de receptores de melatonina tipo 4 (mc4) - Google Patents

compostos derivados de oxazol e oxadiazol e composições farmacêuticas úteis para a liberação oral de composto de peptídeo semelhante a glucagon-1 (glp-1) ou de peptídeo agonista de receptores de melatonina tipo 4 (mc4)

Info

Publication number
BRPI0413676B8
BRPI0413676B8 BRPI0413676A BRPI0413676A BRPI0413676B8 BR PI0413676 B8 BRPI0413676 B8 BR PI0413676B8 BR PI0413676 A BRPI0413676 A BR PI0413676A BR PI0413676 A BRPI0413676 A BR PI0413676A BR PI0413676 B8 BRPI0413676 B8 BR PI0413676B8
Authority
BR
Brazil
Prior art keywords
peptide
glucagon
receptor agonist
glp
oxazole
Prior art date
Application number
BRPI0413676A
Other languages
English (en)
Inventor
Mcneil Mcgill John Iii
Jeff Thrasher Kenneth
Nickolaus Jungheim Louis
Valluri Muralikrishna
Jason Herr Robert
Original Assignee
Lilly Co Eli
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Emisphere Tech Inc filed Critical Lilly Co Eli
Publication of BRPI0413676A publication Critical patent/BRPI0413676A/pt
Publication of BRPI0413676B1 publication Critical patent/BRPI0413676B1/pt
Publication of BRPI0413676B8 publication Critical patent/BRPI0413676B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"composto, e, composição farmacêutica". a presente invenção diz respeito a novos compostos, métodos e formulações úteis para a liberação oral de um composto glp-1 ou de um peptídeo agonista mc4.
BRPI0413676A 2003-08-20 2004-08-18 compostos derivados de oxazol e oxadiazol e composições farmacêuticas úteis para a liberação oral de composto de peptídeo semelhante a glucagon-1 (glp-1) ou de peptídeo agonista de receptores de melatonina tipo 4 (mc4) BRPI0413676B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49653703P 2003-08-20 2003-08-20
US60/496,537 2003-08-20
PCT/US2004/024387 WO2005019212A1 (en) 2003-08-20 2004-08-18 Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide

Publications (3)

Publication Number Publication Date
BRPI0413676A BRPI0413676A (pt) 2006-10-24
BRPI0413676B1 BRPI0413676B1 (pt) 2018-07-24
BRPI0413676B8 true BRPI0413676B8 (pt) 2021-05-25

Family

ID=34216017

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413676A BRPI0413676B8 (pt) 2003-08-20 2004-08-18 compostos derivados de oxazol e oxadiazol e composições farmacêuticas úteis para a liberação oral de composto de peptídeo semelhante a glucagon-1 (glp-1) ou de peptídeo agonista de receptores de melatonina tipo 4 (mc4)

Country Status (12)

Country Link
US (3) US20070293423A1 (pt)
EP (1) EP1658285B1 (pt)
JP (2) JP4754487B2 (pt)
CN (1) CN100398536C (pt)
AT (1) ATE361294T1 (pt)
AU (1) AU2004267044B8 (pt)
BR (1) BRPI0413676B8 (pt)
CA (1) CA2530983C (pt)
DE (1) DE602004006279T2 (pt)
ES (1) ES2286679T3 (pt)
MX (1) MXPA06001916A (pt)
WO (1) WO2005019212A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006269321A1 (en) 2005-07-08 2007-01-18 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
KR100997177B1 (ko) * 2005-07-08 2010-11-29 입센 파마 에스.에이.에스 멜라노코르틴 수용체 리간드
WO2008027958A2 (en) * 2006-08-31 2008-03-06 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP2148692B1 (en) 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
WO2009152079A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EA021897B1 (ru) 2009-11-23 2015-09-30 Палатин Текнолоджиз, Инк. Циклические пептиды, специфичные к рецептору меланокортина-1
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
US10357348B2 (en) * 2013-08-19 2019-07-23 Warren Matthew Leevy Fluid manifold
WO2016160168A1 (en) * 2015-02-20 2016-10-06 Cytec Industries Inc. Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CN105017136A (zh) * 2015-07-24 2015-11-04 陈吉美 一种2-溴-3-甲氧基吡啶的制备方法
EP3580218A1 (en) 2017-02-08 2019-12-18 Bayer CropScience Aktiengesellschaft Novel triazole derivatives
BR112019016241A2 (pt) 2017-02-08 2020-04-07 Bayer Cropscience Ag derivados de triazol e seu uso como fungicidas
CA3052519A1 (en) 2017-02-08 2018-08-16 Andreas Gortz Triazolethione derivatives
AU2018217749A1 (en) 2017-02-10 2019-08-01 Bayer Aktiengesellschaft Composition for controlling harmful microorganisms comprising 1 -(phenoxy-pyridinyl)-2-(1,2,4-triazol-1 -yl)-ethanol derivatives
WO2020020816A1 (en) 2018-07-26 2020-01-30 Bayer Aktiengesellschaft Novel triazole derivatives
CN111793038B (zh) * 2019-04-08 2022-08-12 新发药业有限公司 一种取代噁唑化合物的环保制备方法
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2423709A (en) * 1947-07-08 X-aryl thiazole
US595503A (en) * 1897-12-14 Cross-clevis
US3412193A (en) * 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
WO1988001213A1 (en) * 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5965121A (en) * 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) * 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
CA2260999C (en) * 1996-07-19 2006-07-11 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use in tyrosine kinase inhibition
JP4056589B2 (ja) * 1996-07-19 2008-03-05 武田薬品工業株式会社 複素環化合物、その製造法および用途
CA2319680C (en) * 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) * 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
JP2002534363A (ja) 1999-01-08 2002-10-15 エミスフェアー・テクノロジーズ・インク ポリマー性デリバリー剤及びデリバリー剤化合物
DE60024414T2 (de) * 1999-02-11 2006-06-14 Emisphere Tech Inc Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
WO2000050386A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
AR035016A1 (es) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
HK1048801B (en) 1999-11-05 2009-08-28 Emisphere Technologies, Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
EP1237872B1 (en) 1999-12-16 2008-02-27 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7151191B2 (en) 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
UA80248C2 (en) 2000-06-29 2007-09-10 Compounds and compositions for delivering active agents
DE60129712T2 (de) * 2000-08-23 2008-07-03 Eli Lilly And Co., Indianapolis Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
CA2418104A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
US7022725B2 (en) * 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
JP4148672B2 (ja) * 2000-11-17 2008-09-10 武田薬品工業株式会社 イソオキサゾール誘導体
ES2275621T3 (es) * 2000-12-21 2007-06-16 Glaxo Group Limited Antibioticos macrolidos.
JP4248244B2 (ja) * 2001-02-14 2009-04-02 明治製菓株式会社 １２、１３位変換新規１６員環マクロライド誘導体
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
WO2002096359A2 (en) * 2001-05-30 2002-12-05 Merck & Co., Inc. Piperazine pentanamide hiv protease inhibitors
CA2456985A1 (en) * 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof
US6969057B2 (en) 2001-10-30 2005-11-29 Illinois Tool Works Inc. Method and apparatus for adjusting and positioning air caps
AU2002367426A1 (en) * 2001-12-28 2003-07-24 Takeda Chemical Industries, Ltd. Neurotrophic factor production/secretion accelerator
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
US20060148858A1 (en) * 2002-05-24 2006-07-06 Tsuyoshi Maekawa 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
JP2004277397A (ja) * 2002-05-24 2004-10-07 Takeda Chem Ind Ltd １，２−アゾール誘導体
AU2004251616A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(MC4) agonists and their uses
JP4767850B2 (ja) * 2003-08-20 2011-09-07 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤

Also Published As

Publication number Publication date
CA2530983A1 (en) 2005-03-03
WO2005019212A1 (en) 2005-03-03
EP1658285B1 (en) 2007-05-02
CA2530983C (en) 2012-09-25
AU2004267044B2 (en) 2009-12-03
EP1658285A1 (en) 2006-05-24
CN1832944A (zh) 2006-09-13
JP4754487B2 (ja) 2011-08-24
US20090239798A1 (en) 2009-09-24
CN100398536C (zh) 2008-07-02
BRPI0413676B1 (pt) 2018-07-24
ATE361294T1 (de) 2007-05-15
JP2011207886A (ja) 2011-10-20
US8546581B2 (en) 2013-10-01
US20110190205A1 (en) 2011-08-04
US7947841B2 (en) 2011-05-24
US20070293423A1 (en) 2007-12-20
JP2007502817A (ja) 2007-02-15
DE602004006279T2 (de) 2007-12-27
AU2004267044B8 (en) 2009-12-17
AU2004267044A1 (en) 2005-03-03
DE602004006279D1 (de) 2007-06-14
MXPA06001916A (es) 2006-05-17
ES2286679T3 (es) 2007-12-01
BRPI0413676A (pt) 2006-10-24

Similar Documents

Publication Publication Date Title
BRPI0413676A (pt) composto, e, composição farmacêutica
PE20070498A1 (es) Compuestos derivados de indoles de acilo como antagonistas del receptor de glucagon
RU2319701C2 (ru) ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I
AR045173A1 (es) Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
BR0317451A (pt) Composto, composição farmacêutica, e, uso de um composto
GT200500119A (es) Derivados de tetraazabenzo [e] azuleno y sus analogos
RU2010101232A (ru) Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту
CY1107945T1 (el) Διφαινυλκαρβοξαμιδια υποκατεστημενα με ν-αρυλ πιπεριδινη ως αναστολεις της εκκρισης της απολιποπρωτεϊνης β
DK1531832T3 (da) Terapeutiske sammensætninger til anvendelse ved profylakse eller behandling af diarré
TW200745052A (en) Thyroid hormone receptor agonists
PE20080519A1 (es) Derivados de ester isopropilico del acido 4-[5-metoxi-6-(2-metil-6-[1,2,4]triazol-1-il-piridin-3-ilamino)pirimidin-4-iloxi]-piperidina-1-carboxilico y sus composiciones farmaceuticas
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
DK1349843T3 (da) Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer
PE20040672A1 (es) Derivados de fenil o heteroaril amino alcano
CO6270285A2 (es) Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
BRPI0512058A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
PE20080834A1 (es) Derivados de eter diarilico antagonistas de receptores opioides
PE20091018A1 (es) Novedosos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo y composicion farmaceutica de los mismos para el tratamiento de la eyaculacion prematura
TW200403070A (en) Novel guanidinyl derivatives
AR052330A1 (es) Derivados de adamantano que comprenden quinoleinas sustituidas
DE60319707D1 (de) Pharmazeutische zusammensetzung enthaltend ein benzimidazol-derivat gemischt mit mikrokristalliner cellulose
CR10207A (es) "derivados de acido acético benzo (f) isoindol-2-ilfenil como receptores agonistas de ep4"
NO20080552L (no) GLP-1 farmasoytiske sammensetninger

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EMISPHERE TECHNOLOGIES, INC. (US)

Free format text: TRANSFERIDO DE: ELI LILLY AND COMPANY

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/07/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2684 DE 14-06-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.